Scrip    Clinica    RAJ    Scrip Clinical Research    AnimalPharm
Email ID
Password
Forgotten your password?
Home
Therapy Sector
Generics
Business
Policy & Regulation
Research & Development
International
Europe
|
US/Canada
|
Japan
|
Asia (excluding Japan)
|
Latin America
|
Rest of World
|
International
EVENTS
22 March 2010
London, UK
12 April 2010
Orlando, Florida
13 April 2010
London, UK
JOB OF THE WEEK Promote your vacancy here
DIRECTORY Scrip Directory 2009
Shionogi looks to new products, in-house R&D to weather Crestor expiries
Today
Shionogi is aiming to raise its consolidated net sales to ¥375 billion ($4.1 billion) over the next five years, ahead of a challenging period after 2016 when cholesterol therapy Crestor (rosuvastatin) will be hit by its first patent expiries. The Japanese firm expects to ride the storm largely through a marketing focus on newer products and speeding up the development of key pipeline projects, and says group net sales should recover to hit the ¥600 billion mark 10 years from now. The targets ...
 
Olainfarm is to open Bangkok office to expand in Asia
17 March 2010
Latvia's second-largest pharmaceutical manufacturer Olainfarm is to open a representative office in Bangkok, Thailand, to maintain sales growth in Asia and diversify risks. Its chairman Valerijs Maligins said that the opening of the new office, which will control operations in Vietnam and ...
UNITAID funding could be doubled through US traveller donation initiative
17 March 2010
The international drug purchasing facility UNITAID could potentially double its budget through an innovative financing initiative based on voluntary donations from US airplane passengers. UNITAID has created a budget of $1.3 billion over the past three years. It receives more than 70% of its ...
 
US court tosses out FTC's challenge to alleged "pay-for-delay" Androgel settlement
26 February 2010
A US federal judge has thrown out a Federal Trade Commission antitrust lawsuit alleging that Abbott Laboratories' Solvay unit conspired with generic drug makers to delay competition for its testosterone supplement Androgel. Judge Thomas Thrash of the US District Court for the Northern District of ...
Basilea and J&J terminate Zeftera deal after CHMP negative opinion
22 February 2010
The EU's CHMP has refused to endorse the approval of Basilea Pharmaceutica 's intravenous broad-spectrum cephalosporin antibiotic Zeftera (ceftobiprole) for the treatment of complicated skin and skin structure infections. The decision has prompted Cilag (a Johnson & Johnson subsidiary) – to which ...
 
Shionogi looks to new products, in-house R&D to weather Crestor expiries
Today
Shionogi is aiming to raise its consolidated net sales to ¥375 billion ($4.1 billion) over the next five years, ahead of a challenging period after 2016 when cholesterol therapy Crestor (rosuvastatin) will be hit by its first patent expiries. The Japanese firm expects to ride the storm largely ...
Daiichi Sankyo sees new products, Ranbaxy taking sales to $12 billion level in three years
15 March 2010
Daiichi Sankyo is aiming to boost its group operating profit by almost 90% to ¥180 billion ($1.98 billion) in the fiscal year ending March 31st, 2013, on net sales which are seen reaching ¥1,150 billion, a 20% increase over those forecast for the year to this March 31st. Much of the projected ...
 
Olainfarm is to open Bangkok office to expand in Asia
17 March 2010
Latvia's second-largest pharmaceutical manufacturer Olainfarm is to open a representative office in Bangkok, Thailand, to maintain sales growth in Asia and diversify risks. Its chairman Valerijs Maligins said that the opening of the new office, which will control operations in Vietnam and ...
WHO suspension: Shantha says no safety issue with pentavalent vaccine
17 March 2010
Shantha Biotechnics has said that investigations conducted so far by its Q&A cell and the World Health Organization (WHO) suggest that there is "no safety issue" with its pentavalent vaccine, Shan5, procurement of which has been temporarily suspended by the WHO. The WHO had, last week, temporarily ...
 
Emerging markets to make up 48% of pharma growth, IMS Health says
16 March 2010
IMS Health is predicting that emerging markets will expand by $90 billion during 2009-13, contributing 48% of annual pharmaceutical market growth in 2013, a jump from 37% in 2009. This comes at time when many multinational pharma firms are looking to these markets –with their rising GDPs, ...
Pantoprazole produces mixed results for Nycomed
02 March 2010
Pantoprazole (Protonix) proved to be both a boon and blight on Nycomed 's financial performance in 2009. The gastro-oesophageal reflux disease treatment struggled to cope with its loss of exclusivity in many key European markets, but still drove growth in Latin America. The privately held Swiss ...
 
Patient information – what price public trust?
17 March 2010
Trust and respect seem to be in short supply these days, at least where certain sectors of society are concerned. At international level, the banking industry is under a dark cloud of public opprobrium for its role in the global financial crisis. In the UK, the reputation of politicians, already ...
WHO suspension: Shantha says no safety issue with pentavalent vaccine
17 March 2010
Shantha Biotechnics has said that investigations conducted so far by its Q&A cell and the World Health Organization (WHO) suggest that there is "no safety issue" with its pentavalent vaccine, Shan5, procurement of which has been temporarily suspended by the WHO. The WHO had, last week, temporarily ...
 

Market Insight: Big pharma hit by Greece's fiscal crisis
09 March 2010

Hospitals' failure to pay pharmaceutical companies and newly announced price cuts are just some of ...

 Market Insight - Fear gives way to prudence a...

How to run clinical trials in the Middle East - Jordan
04 March 2010

Jordan has a population of 6.35 million and its GDP per capita is $5,000, while its healthcare ...

Market Insight - Pharma sector in Turkey to shrink 25% under tough conditions
02 March 2010

The pharmaceutical industry has long eyed Turkey as one of its key emerging markets, but recent ...

Private investment round-up: February 2010
15 March 2010
Just as it appeared that the private investment market was beginning to rebound after last year's ...

European Medicines Agency and logos: snakes, DNA and the pestle and mortar
22 December 2009
Elizabeth Sukkar
Logos are said to be an important part of an organisation's branding. Really good logos contribute ...

Face to Face with Sandoz's "growth guy" Jeff George
04 March 2010
Eleanor Malone
Jeff George took over as head of Sandoz, Novartis's generics business, in late 2008. With a big ...

DIA Annual Meeting 2008
09 May 2008
Boston: The importance of place, The new clinical researchers and Discussing the big issues

© 2010 Informa plc. All rights reserved.
This site is owned and operated by Informa plc ("Informa") whose registered office is Mortimer House, 37-41 Mortimer Street, London, W1T 3JH. Registered in England and Wales. Number 3099067. UK VAT Group: GB 365 4626 36
Home
Therapy Sector
Generics
Business
Policy & Regulation
Research & Development
International
Terms & Conditions
Privacy Policy
Sitemap
About Us
Advertise
Subscribe
Scrip
Clinica
RAJ
Scrip Clinical Research
Animal Pharm